



Press Release

Livingstone Health and ASX-Listed Osteopore to Jointly Develop Regenerative 3D-Printed Product, Solutions, and Therapy For Bone and Tissue Healing

Singapore, 20 June 2022 – SGX Catalist-listed Livingstone Health Holding Limited (“**Livingstone Health**” or the “**Group**”) announced today it will collaborate with Australian Securities Exchange-listed Osteopore Limited (“**Osteopore**”) to further develop the utilisation of 3D-printed micro-structures for bone and tissue healing and regeneration.

The two parties signed a Memorandum of Understanding (“MoU”) to combine the expertise of Livingstone Health’s orthopaedic surgeons and Osteopore’s innovations in natural tissue regeneration. Based in Australia and Singapore, Osteopore’s innovations include bioresorbable implants made from patented scaffolds that are 3D-printed.

These scaffolds dissolve naturally over time, leaving only natural, healthy bone tissue. This innovation improves surgical outcomes and lowers medical costs, as it significantly reduces post-surgery complications compared to traditional procedures such as bone grafting and permanent implants.

Within the Livingstone Health's orthopaedic team, two specialists – Dr. Edwin Tan and Dr. James Tan – intend to apply two of Osteopore’s products in two upcoming surgeries, marking the first orthopaedic application of Osteopore implants in Singapore. The first is Osteomesh®, a rigid yet flexible bioresorbable scaffold, which will be used for tendon repair, including rotator cuff and Achilles tendon. The second is Osteopore’s latest product, a synthetic fibular strut graft which will be used for bone reconstruction in the upper and lower limbs.

Dr. Wilson Tay, CEO of Livingstone Health, said, “It is an exciting partnership which puts Livingstone Health at the forefront of orthopaedic technology and is in line with the Group's commitment to providing holistic healthcare for our patients. We look forward to working closely with Osteopore to develop cutting-edge products that accelerate healing and reduce the risk of complications patients face post-surgery.”

Mr. Mark Leong, Executive Chairman of Osteopore, said, “We are pleased to be collaborating with the Livingstone Health orthopaedic team and leverage their expertise to bring our proven tissue regeneration technology to their patients. We look forward to entering the orthopaedic space in Singapore having already successfully conducted several world-first orthopaedic surgeries in Australia, where our scaffolds helped regenerate a 36cm shin bone.”

The signing of the MoU is not expected to have any material impact on the net tangible assets per share or earnings per share of the Group for the current financial year ending 31 July 2022.



About Livingstone Health

Livingstone Health Holdings Limited. (“Livingstone Health” and together with its subsidiaries, the “Group”) is a Singapore-based multidisciplinary healthcare group whose core competencies include Aesthetics & Wellness, Anaesthesiology & Pain Management, Family Medicine, Internal Medicine, and Orthopaedic Surgery.

The name “Livingstone” is inspired by the succulent plant Lithops, also known as “living stones”. They symbolise the Group’s resilience, growth and determination to be recognised as a trusted integrated healthcare provider for patients, as well as a centre of excellence of growth opportunities for medical professionals.

The Group has 19 medical doctors and healthcare professionals, practising at 14 medical clinics, one medical spa, one health screening center, and a Podiatry and Physio Clinic located at convenient and accessible locations throughout Singapore. It also provides healthcare consultancy design services within the region.

For more information, please visit: www.livingstonehealth.com.sg.

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

Media & Investor Contact Information

WeR1 Consultants Pte Ltd

1 Raffles Place #02-01
One Raffles Place Mall Suite 332
Singapore 048616
Isaac Tang, livingstone@wer1.net M: +65 9748 0688

This press release has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the “Sponsor”). This press release has not been examined or approved by the SGX-ST, and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Tay Sim Yee (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542.